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Introduction: We present a fully automated method for deriving quantitative measures of background parenchymal
enhancement (BPE) from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and perform a
preliminary evaluation of these measures to assess the effect of risk-reducing salpingo-oophorectomy (RRSO) in a
cohort of breast cancer susceptibility gene 1/2 (BRCA1/2) mutation carriers.
Methods: Breast DCE-MRI data from 50 BRCA1/2 carriers were retrospectively analyzed in compliance with the Health
Insurance Portability and Accountability Act and with institutional review board approval. Both the absolute (| |) and
relative (%) measures of BPE and fibroglandular tissue (FGT) were computed from the MRI scans acquired before and
after RRSO. These pre-RRSO and post-RRSO measures were compared using paired Student’s t test. The area under the
curve (AUC) of the receiver operating characteristic (ROC) was used to evaluate the performance of relative changes in
the BPE and FGT measures in predicting breast cancer that developed in these women after the RRSO surgery.
Results: For the 44 women who did not develop breast cancer after RRSO, the absolute volume of BPE and FGT had
a significant decrease (P < 0.05) post-RRSO, whereas for the 6 women who developed breast cancer, there were no
significant changes in these measures. Higher values in all BPE and FGT measures were also observed post-RRSO for
the women who developed breast cancer, compared with women who did not. Relative changes in BPE percentage
were most predictive of women who developed breast cancer after RRSO (P < 0.05), whereas combining BPE percentage
and |FGT| yielded an AUC of 0.80, higher than BPE percentage (AUC = 0.78) or |FGT| (AUC = 0.66) alone (both P > 0.02).
Conclusions: Quantitative measures of BPE and FGT are different before and after RRSO, and their relative changes are
associated with prediction of developing breast cancer, potentially indicative of women who are more susceptible to
develop breast cancer after RRSO in BRCA1/2 mutation carriers.* Correspondence: despina.kontos@uphs.upenn.edu
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Accurate risk assessment is critical for women at high risk
of breast cancer to tailor risk reduction interventions [1].
High-risk women include those who have known genetic
mutations (e.g., breast cancer susceptibility gene 1/2
[BRCA1/2]) or a strong family history of breast cancer [2].
In particular, women with BRCA1/2 mutations are at a
remarkably high lifetime risk, estimated to be up to 57 %
for BRCA1 carriers and 49 % for BRCA2 carriers [3, 4].
Several risk reduction interventions are currently being
used clinically, ranging from the less aggressive, such as
lifestyle changes [5] and chemoprevention [6, 7], to those
that are more aggressive, such as oophorectomy [8] and
prophylactic mastectomy [9]. Although these interven-
tions are effective in reducing cancer risk [10–12], they
also have substantial side effects. For example, tamoxifen
can induce endometrial cancer [13]; oophorectomy is
associated with early menopause symptoms [14]; and
prophylactic mastectomy is associated with morbidity
and psychosocial effects [15].
A major current limitation is that it is uncertain what
level of intervention is effective for individual women
[16]. Given the lack of methods to weigh the benefit
versus risks for different interventions, women decide
based on their own preference and perception of risk
rather than on an evidence-based approach. As a result,
some women may be overtreated by undergoing unneces-
sary prophylactic mastectomies, whereas others may be
undertreated and end up developing breast cancer.
Risk-reducing salpingo-oophorectomy (RRSO) is a surgical
procedure in which the ovaries and fallopian tubes are
removed to help prevent ovarian and breast cancer in
women. RRSO is recommended for BRCA mutation
carriers (by the age of 35 to 40 years) and has been
shown to reduce the risk of developing breast cancer
by approximately 50 % [17, 18], with higher benefits
associated with earlier age at surgery, and that of
ovarian and/or fallopian tube cancer by approximately
80 % to 90 % [19]. Yet, there is no established standard to
identify women most likely to benefit versus the ones
who may need other aggressive interventions, such as
prophylactic mastectomy. Therefore, methods are highly
needed to better determine the likelihood of response
to risk reduction interventions to better guide risk
management decisions.
Dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) characterizes both the anatomic and physio-
logic activity of breast tissue [20]. Whereas mammographic
density has been established through multiple studies as a
risk factor for breast cancer [21, 22], mammography cannot
differentiate the fibrous connective breast tissue from the
hormonally responsive glandular tissue. In DCE-MRI, the
glandular tissue enhances in the image as background
parenchymal enhancement (BPE). Therefore, in addition toquantifying the overall fibroglandular tissue (FGT) content,
MRI could provide a more sensitive biomarker of hormonal
tissue activity by also quantifying BPE. Currently, MRI BPE
and FGT are mainly estimated visually using the American
College of Radiology Breast Imaging Reporting and Data
System (BI-RADS) [23–25]. Although clinically useful, this
kind of qualitative assessment is coarse, subjective, and has
large inter- and intrareader variability [23], which makes it
difficult to standardize. The purpose of this study was to
present a fully automated method for deriving quantitative
measures of BPE from breast DCE-MRI and perform
a preliminary evaluation of these measures to assess the
effect of RRSO in a cohort of BRCA1/2 mutation carriers.
Methods
Dataset and imaging protocols
This retrospective study was compliant with the Health
Insurance Portability and Accountability Act and approved
by the University of Pennsylvania Abramson Cancer
Center’s Clinical Trials Scientific Review and Monitoring
Committee and Institutional Review Board with a waiver
of consent granted, owing to the retrospective nature of
the study and the minimal perceived risk to subjects.
A cohort of 55 BRCA1/2 mutation carriers was retro-
spectively identified. All women who underwent RRSO
and had at least one pre-RRSO MRI and one post-RRSO
MRI scan available during 1999–2011 at our institution
were included in this study. Exclusion criteria were:
(1) women with RRSO before their earliest MRI, (2) any
prior history of radiated breast, and (3) bilateral mastec-
tomy, if that was performed before undergoing at least
one MRI after RRSO intervention. Women who had only
pre-RRSO MRI scans or post-RRSO MRI scans, but not
both, were also excluded. The age range of the study
cohort was from 40 to 76 years, and the average was 51.8
years. Of these 55 women, 9 were diagnosed with breast
cancer at a median of 4.8 years (range 1.8–13.3 years) of
follow-up after RRSO. Each woman had a pre-RRSO
DCE-MRI scan and a post-RRSO DCE-MRI scan available.
Seventy-six percent (38/50) of the women were clinically
pre-menopausal at the time of pre-RRSO imaging.
Pre-RRSO MRI was performed ideally in the second
week of the menstrual cycle in premenopausal women, as
studies have shown that the least amount of BPE is seen in
this time period [26, 27]. All women were clinically
post-menopausal following RRSO. Two women (4 %)
were receiving exogenous hormone replacement therapy
before their pre-RRSO and post-RRSO scans. The first
immediate MRI after RRSO is referred to herein as the
post-RRSO MRI scan. The mean time to the post-RRSO
MRI scan was 8.3 ± 7 months. Of the 55 women, 5
(including 3 women who developed breast cancer
after RRSO) were excluded from our analysis because
their DCE pre-contrast series in either the pre-RRSO
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to quantitatively compute BPE. Therefore, a total of 100
DCE-MRI scans of 50 women (including 6 women who
developed breast cancer after RRSO) were analyzed.
Women were scanned in the sagittal plane in the prone
position in either a 1.5-T scanner (GE LX Echospeed, GE
Healthcare, Nutley, NJ, USA, or Siemens Sonata, Siemens
Medical Solutions, Malvern, PA, USA) or a 3-T scanner
(Siemens Trio) using a dedicated surface breast coil array,
including bilateral, fat-suppressed, T2-weighted (6530/86
[repetition time in milliseconds/echo time in milliseconds])
and slab interleaved, 3D, fat-suppressed, spoiled gradient
echo sequences. The breast MRI scans of the study cohort
were acquired with a range of parameters that evolved over
the years (matrix size 512 × 512, 512 × 256, 256 × 256, or
192 × 192; slice thickness 2–4 mm; field of view 18–22 cm;
flip angle 15° or 20°). Sequential post-contrast MRI series
were acquired for approximately 6 min after contrast injec-
tion (Omniscan; GE Healthcare) per standard clinical
protocol at our institution. A rapid bolus injection of 0.1
mmol/kg gadopentetate dimeglumine (Omniscan) followed
by a 10-ml saline flush was administered in all women. The
subtraction images (i.e., post-contrast minus pre-contrast;
“SUB” for short) were routinely available for our analysis.
MRI acquisition was fairly consistent in terms of the major
aspects of the acquisition protocol, such as the MRI vendor,
field strength, temporal resolution, and dynamic contrast
enhancement protocol between the paired MRI scans
of the same patient, whereas slight differences were
introduced over time, owing to the technical evolution of
the MRI protocol, mainly in matrix size (spatial resolution)
and size of field of view as stated above, which was shown
in previous studies not to have a major impact to our
quantitative analysis [28, 29].
Computerized quantification of background parenchymal
enhancement
As an initial step, we used our previously validated fully
automated method to segment and quantitatively measure
FGT [28, 29]. Briefly, an edge extraction algorithm was first
applied in the T1-weighted, non-fat-suppressed MRI scans
to segment the breast from the image background and the
chest wall [28], from which the absolute total breast
volume (|Breast|) is estimated (in cubic centimeters). The
fibroglandular tissue was then segmented within the breast
volume using an atlas-aided fuzzy C-means algorithm [29].
The absolute volume (in cubic centimeters) of the
segmented FGT (|FGT|) is computed, and FGT percentage
was derived by using the following formula:
FGT% ¼ FGTj j
Breastj j  100 ð1Þ
Once FGT was segmented, we proceeded to compute
BPE automatically based on the segmented FGT content.In our algorithm, BPE on the DCE-MR images was esti-
mated by examining the relative difference of each voxel’s
intensity (denoted by I in equation 2) in the SUB image
relative to the intensity in the corresponding pre-contrast
image. This voxel-wise enhancement ratio (R%) measures
the relative intensity change as follows:
R% ¼ Ipost‐ Ipre
Ipre
 




Because in principle only the FGT portion of the back-
ground parenchymal tissue should be enhance by the
contrast agent uptake, we estimated the enhancement
specifically over the FGT region. For this purpose, the
FGT segmentation obtained in the T1-weighted, non-fat-
suppressed images was translated to the DCE series
images after applying a rigid registration step between the
two scans [30]. Therefore, we could identify the enhancing
voxels over the FGT region that had a value equal to or
greater than a predefined enhancement ratio threshold
R%cutoff, and BPE was computed as the total volume





We then estimated the absolute total volume of BPE
(|BPE|) and derived the measure of BPE% as follows:
BPE% ¼ BPEj j
Breastj j  100 ð4Þ
A total of four quantitative measures were generated
based on the above definitions: absolute and relative
volumes of FGT, denoted as |FGT|, FGT%, respectively;
and absolute and relative volumes of BPE, denoted as
|BPE| and BPE%, respectively (Fig. 1).
In typical clinical protocols, there may be multiple
post-contrast time points and SUB images available [20].
Multiple post-contrast images acquired at different time
points reflect changes in signal intensity induced by the
uptake of the contrast agent over time [31, 32]. Therefore,
in our analysis, we evaluated the BPE estimated using
the first and third time point SUB images for the
purpose of comparing the effect that early versus delayed
tissue enhancement may have on the estimation of BPE
(i.e., SUB 1 vs. SUB 3).
Statistical analysis
As there is currently no established value for the R%cutoff,
we estimated BPE using values for the R%cutoff ranging
from 0 % to 100 % with increments of 10 %. For each of
the FGT and BPE measures, the mean (±SD) was com-
pared between the pre- and post-RRSO MRI scans for the
44 women who did not develop breast cancer post-RRSO
versus the 6 women who did, using a two-sided Student’s
Fig. 1 Illustration of our fully automated computer algorithm for quantifying magnetic resonance imaging (MRI) background parenchymal
enhancement (BPE) and fibroglandular tissue (FGT). Representative 2D and 3D tissue segmentations in selected breast MRI scans are shown.
a A breast MRI slice of the T1-weighted sequence. b Segmentation of the whole breast (red contour) and FGT (green contour). c 3D display of
FGT (green) relative to the whole breast (red). d This dynamic contrast-enhanced MRI subtraction (SUB) image corresponds to the T1 slice
shown in (a). e BPE (purple contour) estimated over the FGT area in the SUB image. f 3D display of BPE (purple), FGT (green), and whole breast (red)
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differences in contrasting the two independent variables
(i.e., developing vs. not developing breast cancer and
pre-RRSO status vs. post-RRSO status), analysis of
variance (ANOVA) was also performed. Given the
preliminary nature of our study, we also used the
false discovery rate (FDR), a family-wise approach, to
correct for multiple comparisons. In addition, the relative
difference (i.e., [post-RRSO − pre-RRSO]/pre-RRSO) in
each FGT and BPE measure was computed for all women,
and these relative differences were evaluated for their
association with the odds of developing breast cancer
post-RRSO using logistic regression. Receiver operating
characteristic (ROC) curves were generated, and the area
under the curve (AUC) was derived to evaluate predictive
value in distinguishing women who developed breast
cancer after RRSO versus the ones who did not. ROC
curves were generated by using developing versus not
developing cancer post-RRSO as a binary ground truth label
and the output (i.e., the predicted probability of cancer)
generated from the fitted logistic regression model as the
decision variable. DeLong’s test was used to compare the
different AUCs. As a preliminary evaluation, we also sought
to determine if an optimal value for R%cutoff exists that
generates measures most predictive of BPE. Toward this
end, we also used leave-one-out cross-validation (LOOCV)
to compare AUCs computed based on relative changes
of BPE between post-RRSO scans and pre-RRSO scans,derived across the same range of the R%cutoff values
(from 0 % to 100 %; see Additional file 1).
Results
The P values derived from the t test comparing the
BPE-related measures in the pre-RRSO scans versus the
post-RRSO scans for a range of values of the R%cutoff are
shown in Manhattan plots in Fig. 2. As can be seen from
the P value profiles of the full cohort (Fig. 2a), when using
SUB 1 to estimate BPE, there was a consistently significant
(P < 0.05) decrease after the RRSO for |BPE| when the
R%cutoff fell within the range from 0 % to 40 %, and a simi-
lar observation held true for BPE% when the R%cutoff was
in the range of 10 % to 60 %. Likewise, when using SUB 3,
there was a significant decrease of the BPE measures after
RRSO; however, the corresponding ranges of the R%cutoff
where this decrease was significant expanded to an overall
wider range of 0 % to 80 % for |BPE| as well as from 10 %
to 100 % for BPE%. When we examined separately the
women who did not develop breast cancer post-RRSO, we
observed similar trends (Fig. 2b). However, there were no
significant changes in |BPE| for women who developed
breast cancer post-RRSO, regardless of whether SUB 1 or
SUB 3 was used for the |BPE| estimation and across the
entire range of the R%cutoff (Fig. 2c).
The ROC AUCs for predicting the women who developed
breast cancer post-RRSO based on the relative differences
of their BPE measures before and after RRSO are shown in
Fig. 2 Manhattan plot of the P value profiles of paired Student’s t test comparing the pre-RRSO and post-RRSO measures of background paren-
chymal enhancement (BPE) (both |BPE| and BPE %) computed by using a range of values (from 0 % to 100 %) for the R %cutoff, indicating a range
of the R %cutoff values on which the difference between the pre-RRSO and post-RRSO BPE measures become significant (P < 0.05). RRSO,
Risk-reducing salpingo-oophorectomy. a Results for the full cohort (i.e., a total of 50 women). b Results for the 44 women who did not
develop breast cancer post-RRSO. c Results for the 6 women who developed breast cancer post-RRSO. Abbreviation: SUB, Subtraction image
(i.e., post-contrast minus pre-contrast)
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predictive value (AUC 0.78, P = 0.09) for an R%cutoff
of 30 %. This cutoff of 30 % appeared to be consistent and
was further confirmed by the LOOCV-generated AUCs
(see Additional file 1: Figure S1).
For this representative R%cutoff of 30 %, the values of all
MRI measures, including the BPE measures computed inboth SUB 1 and SUB 3, are shown in Table 1. In terms of
the FDR-corrected P values, for the subcohort of 44
women who did not develop breast cancer post-RRSO,
BPE measures computed in SUB 3, as well as |FGT|, had
a significant decrease (P < 0.05) post-RRSO. For the six
women who developed breast cancer post-RRSO, all FGT
(|FGT| and FGT%) and BPE (|BPE| and BPE%) measures
Fig. 3 The areas under the receiver operating characteristic curves (AUCs) of the predictive performance using relative changes in the different
background parenchymal enhancement (BPE) measures across the entire range of R %cutoff values were employed to predict women who developed
breast cancer post-RRSO, where BPE % estimated from subtraction image 1 (i.e., post-contrast minus pre-contrast [SUB 1]) shows the highest predictive
value (AUC 0.78, P = 0.09) for an R %cutoff of 30 %
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significant decrease in BPE% computed in SUB 3. In terms
of the ANOVA, BPE% SUB1 stood out as the most statis-
tically significant measure when we jointly contrasted the
pre-/post-RRSO status and developing versus not
developing cancer groups. The women who developed
breast cancer had higher average values in all the BPE and
FGT measures post-RRSO than the women who did not
(P = 0.046). Examples of FGT and BPE pre-RRSO andTable 1 Comparison of the fibroglandular tissue and background p
reducing salpingo-oophorectomy
|FGT| [cm3] FGT % [ %]
44 women who did not develop
breast cancer post-RRSO
Pre-RRSO 83.2 ± 63.8 11.3 ± 8
Post-RRSO 60.4 ± 50.1 10.3 ± 7




6 women who developed
breast cancer post-RRSO
Pre-RRSO 65.1 ± 60.2 11.6 ± 3
Post-RRSO 72.9 ± 38.2 11.2 ± 7




ANOVA P-value 0.83 0.24
FDR-corrected ANOVA P-value 0.83 0.29
AUC 0.66 0.57
Data are presented as mean ± SD, where background parenchymal enhancement (
images 1 and 3 (i.e., post-contrast minus pre-contrast; SUB 1 and SUB 3, respectivel
post-RRSO measures for each group. In analysis of variance, the P values represent
pre-RRSO vs. post-RRSO status as the two independent variables. False discovery ra
comparisons. AUC refers to the area under the receiver operating characteristic cur
cancer after RRSO, based on the relative differences (i.e., [post-RRSO − pre-RRSO]/pr
Risk-reducing salpingo-oophorectomypost-RRSO are shown in Figs. 4 and 5 for selected patients
in each subgroup.
Finally, for the R%cutoff of 30 %, we also tested the
combination of the most predictive measures of FGT and
BPE (i.e., |FGT| and BPE% SUB 1) as joint predictors in a
multivariable logistic regression model, which yielded an
improved AUC of 0.80 (P = 0.08 for |FGT| and P = 0.09
for BPE% SUB 1), but the AUCs were not statistically
significantly higher (P > 0.2) than the AUC of either thearenchymal enhancement measures before and after risk-
|BPE| SUB 1 [cm3] BPE % SUB 1 [ %] |BPE| SUB
3 [cm3]
BPE % SUB 3 [ %]
.1 28.2 ± 44.2 3.8 ± 4.5 43.0 ± 49.7 6.0 ± 5.9
.5 12.2 ± 11.8 2.3 ± 1.8 21.0 ± 15.2 3.9 ± 2.5
0.027 0.045 0.005 0.015
0.06 0.078 0.03 0.046
.8 26.7 ± 12.6 7.3 ± 4.6 40.0 ± 31.3 8.2 ± 3.8
.6 20.5 ± 19.2 3.3 ± 2.3 33.6 ± 20.1 5.4 ± 3.2
0.48 0.035 0.68 0.0096
0.64 0.070 0.82 0.038
0.058 0.0057 0.021 0.023
0.087 0.034 0.046 0.046
0.48 0.78 0.66 0.65
BPE) is estimated using the representative R %cutoff of 30 % for subtraction
y). P values were derived by paired Student’s t test comparing pre-RRSO and
our jointly contrasting the groups developing vs. not developing cancer and
te (FDR)-corrected P values are also provided as a means to adjust for multiple
ve for the logistic regression models to predict women who developed breast
e-RRSO) in each measure. Abbreviation: RRSO,
Fig. 4 Representative examples of fibroglandular tissue (FGT) and background parenchymal enhancement (BPE) from a magnetic resonance
imaging (MRI) slice obtained pre-RRSO and post-RRSO in a woman who did not develop breast cancer after undergoing risk-reducing
salpingo-oophorectomy (RRSO). FGT is circumscribed by green contours. BPE is estimated in both the first and third subtraction series
(SUB 1 and SUB 3, respectively). This 40-year-old (at time of RRSO) woman had her pre-RRSO MRI at 6 months before RRSO and her post-RRSO
MRI at 1 month after RRSO. She had no personal history of breast cancer or other cancer and had no breast cancer diagnosis for up to 9 years
of post-RRSO follow-up. This example illustrates that there was a decrease of BPE and FGT after her RRSO. The volumetric pre-RRSO BPE % values
were 1.5 % (SUB 1) and 6.5 % (SUB 3) and after RRSO, and BPE % values were 0.6 % (SUB 1) and 3.6 % (SUB 3)
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P = 0.03) alone (Fig. 6). The Spearman correlation between
the |FGT| and BPE% SUB 1 was 0.09 (p = 0.5).
Whereas there was no significant decrease in |BPE|
for the women who developed breast cancer after RRSO,
there was a significant change in BPE%. This was an
interesting observation, which we investigated further
by also looking into potential changes of the total
breast volume. We found that the total breast volume
(|Breast|) also changed after RRSO (Fig. 7). Specifically,
whereas the total breast volume after RRSO also decreased
for the women who did not develop breast cancer
(P = 0.01), our preliminary analysis suggested that the
total volume had no significant change for the women
who developed breast cancer (P = 0.82).
Discussion
In our study, quantitative measures of BPE and FGT were
computed with data derived from breast DCE-MRI using
a fully automated computerized method, and they were
subsequently evaluated for a pilot cohort of BRCA1/2 mu-
tation carriers to assess the effect of RRSO. Although this
is a preliminary study with a small discovery datasetrequiring further validation in a larger cohort, overall our
results indicate that these measures could be useful for
assessing response to RRSO and potentially identifying the
women who may still be susceptible to developing breast
cancer after their surgery. In terms of the t test P values
shown in Table 1, the absolute volume of BPE and FGT
appeared to have a significant decrease post-RRSO for
women who did not develop breast cancer (with a median
of 4.8 years of follow-up), whereas there were no signifi-
cant changes in these measures for women who developed
breast cancer post-RRSO. The 6 women who developed
breast cancer had higher average values for all the BPE
and FGT measures post-RRSO compared with the 44
women who did not. It is also interesting to note that
FGT% and |BPE| (both on SUB 1 and SUB 3) started off
with similar average values before RRSO in both groups
and that the significant decrease of |BPE| was observed
only in the group of the 44 women who did not develop
breast cancer post-RRSO. In the evaluation of the relative
changes of these MRI measures in predicting breast
cancer development post-RRSO, it appeared that the
combination of BPE% SUB1 and |FGT| provided the high-
est prediction accuracy—higher than either of them alone.
Fig. 5 Representative examples of fibroglandular tissue (FGT) and background parenchymal enhancement (BPE) from a magnetic resonance imaging
(MRI) slice obtained pre-RRSO and post-RRSO in a woman who developed breast cancer after undergoing risk-reducing salpingo-oophorectomy
(RRSO). FGT is circumscribed by green contours. BPE is estimated in both the first and third subtraction series (SUB 1 and SUB 3, respectively).
This 36-year-old (at time of RRSO) woman had her pre-RRSO MRI at 1 month before RRSO and her post-RRSO MRI at 6 months after RRSO.
Breast cancer (ductal carcinoma in situ) was diagnosed in her right breast 6 years after RRSO, and her final pathologic examination showed
in situ carcinoma with 2 foci of microinvasion (<0.1 cm). This example shows no decrease of BPE and FGT after RRSO. The volumetric pre-RRSO
BPE % values were 10.7 % (SUB 1) and 10.6 % (SUB 3) and after RRSO, and BPE % values were 7.1 % (SUB 1) and 8.5 % (SUB 3)
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that they may be independently associated to breast can-
cer, although, owing to the marginal statistical signifi-
cance, larger studies with sufficient sample size are
warranted to further validate this claim. Overall, our
results indicated that BPE% SUB1 was the most significant
measure in predicting breast cancer after RRSO, and
specifically that the percentage measures of BPE, particu-
larly quantified in the first post-contrast SUB sequence
(i.e., BPE% SUB 1), may be most relevant as an imaging
biomarker for assessing the effect of RRSO.
Our observations are in accordance with previously
reported reader studies [24, 33] in which the 4-scale
qualitative BI-RADS assessment was used to evaluate
changes in BPE and FGT between pre-RRSO and
post-RRSO MRI scans on BRCA1/2 mutation carriers.
In their study of 55 patients, DeLeo et al. [33] reported a
significant reduction in BPE but no significant change in
FGT. In their study of 18 patients, Price et al. [24] observed
significant decreases in both BPE and FGT after RRSO and
that BPE had a greater extent than FGT in the observed
decrease. In addition, no previous study researchers have
evaluated the changes in BPE and FGT measures betweenpre-RRSO and post-RRSO scans for predicting the
development of breast cancer post-RRSO, which is
an important clinical endpoint of interest. In the reader
studies [24, 33], only a fair to moderate interreader
agreement (κ = 0.3–0.6) was reported for the qualitative
assessment of BPE. On the contrary, fully automated
computerized methods, such as the ones evaluated in
our study, can provide objective and reproducible
quantitative measures that alleviate the subjectivity of
intra- and inter reader variability in the qualitative
MRI assessment. In addition, fully automated assessment
is more time-efficient: Automated quantification of FGT
and BPE in our study took approximately a total of 5 min
per scan, compared, for example, with manual segmenta-
tion of FGT previously reported at about 55 min per MRI
scan [29]. As such, automated methods are critical to
accelerating the translation of these imaging measures into
routine clinical application. In recent studies, researchers
have also reported that higher measures of BPE and FGT
may indicate a higher risk of developing breast cancer [23].
Along these lines, our results suggest that our measures
could be used to determine which women may be more
likely to develop breast cancer after RRSO and could
Fig. 7 Whole-breast volume (|Breast|) changes after risk-reducing salpingo-
women who did not develop breast cancer post-RRSO but a non-significan
The changes may be due to overall changes in the breast disuse, including
RRSO surgery
Fig. 6 Area under the receiver operating characteristic curve (AUC)
for the logistic regression models to predict women who developed
breast cancer after risk-reducing salpingo-oophorectomy (RRSO),
based on combination of relative changes (i.e., [post-RRSO −
pre-RRSO]/pre-RRSO) of their absolute fibroglandular tissue (|FGT|)
and background parenchymal enhancement first subtraction series
(BPE % SUB 1) measures (i.e., best in Table 1). Combining BPE % and
|FGT| yielded a higher AUC of 0.80 than that of BPE % (AUC 0.78) or
|FGT| (AUC 0.66) alone (both P > 0.2)
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ventions such as prophylactic mastectomy.
We also compared the effects of BPE quantified on
SUB 1 versus SUB 3. Whereas we observed similar
trends in changes for both |BPE| and BPE% (Fig. 2),
there was a difference in the range of the R%cutoff at
which these changes became significant (P < 0.05). The
larger range observed in SUB 3 may reflect that there is
more uptake of contrast agent in the breast tissue owing
to a longer uptake time; likewise, this may also explain
the smaller range observed in SUB 1, on which the
amount of contrast enhancement was less owing to a
shorter uptake time. At the same time, we observed
that the BPE% derived from SUB 1 was the most pre-
dictive measure among all BPE measures evaluated.
Therefore, determining whether measures from the early-
stage or, alternatively, delayed-stage post-contrast series
are more predictive of a response to RRSO requires
further validation.
As ovaries are removed, RRSO results in great reduction
in the amount of the circulation of the endogenous
hormones estrogen and progesterone. As a result of
this effect, all 50 women essentially became clinically
post-menopausal after RRSO. Studies have shown that
BPE and FGT decrease after menopause in great propor-
tions of healthy women [34] and that BPE increases in
post-menopausal women who have had recent hormone
replacement therapy [35]. Therefore, this may explain the
post-RRSO changes of BPE and FGT observed in ouroophorectomy (RRSO) showing a significant decrease for the 44
t increase for the 6 women who developed breast cancer after RRSO.
changes in the fat content, induced by hormonal changes due to the
Wu et al. Breast Cancer Research  (2015) 17:67 Page 10 of 11study as an effect of the reduction in the corresponding
endogenous reproductive hormone levels. As for the total
breast volume changes, whereas the biological basis of the
observation cannot be interpreted solely on the basis of
our study, we speculate that it may be due to overall
changes in the breast disuse, including changes in the fat
content, induced by hormonal changes resulting from the
RRSO surgery.
Limitations of our study must also be noted. In this pilot
study, we used a relatively small retrospective cohort in
which we had only a few women who developed breast
cancer post-RRSO, which therefore limited our power to
derive conclusive interpretations of the related findings.
With such a small dataset, the P values should be assessed
with caution. That being said, with this preliminary evalu-
ation, mainly for hypothesis generation, we believe our
results will be instrumental in guiding the design and
appropriate power calculation for a larger prospective study.
In addition, in this exploratory study, our initial investiga-
tion was focused on the main effect analysis of RRSO on
BPE. To investigate the direct effect of RRSO, it will be
important in future studies to adjust for factors such as
exogenous hormonal treatment, medications, diet, and
other possible confounding factors. In addition, as no estab-
lished R%cutoff currently exists, we examined the effects of
BPE using a range for R%cutoff from 0 % up to 100 %, which
may have introduced a bias via multiple comparisons. Given
the preliminary nature of our study mainly for generating
hypotheses, we used a family-wise approach (i.e., FDR)
because it was more appropriate to adjust our significance
threshold for multiple comparisons. In our preliminary
evaluation, we found that there is a range of values
for R%cutoff in which all these measures were able to
achieve statistical significance (Fig. 2) and that a 30 %
R%cutoff had the best predictive performance for our study
population. On the basis of the promising performance of
our method, further work is warranted to fully optimize
algorithm parameters and validate our findings in larger
populations. Finally, these computer algorithms require
additional evaluation to determine generalizability to a
range of different MRI protocols and scanners.
Conclusions
Quantitative measures of BPE and FGT were computed
using data derived from breast DCE-MRI scans using a fully
automated computerized method and were subsequently
evaluated for a pilot cohort of BRCA1/2 mutation carriers
for assessing the effect of RRSO. The relative changes of the
BPE and FGT between post-RRSO and pre-RRSO are asso-
ciated with predicting development of breast cancer after
RRSO. Our results suggest that these measures may be use-
ful for predicting response to RRSO and ultimately assisting
in clinical decision making regarding risk-reducing inter-
ventions for BRCA1/2 carriers. We envision a setting inwhich individualized risk assessment and patient education
are combined to empower women with knowledge about
their personal risk while providing much-needed quantita-
tive tools for clinicians. As it is currently recommended that
high-risk women also undergo annual MRI screening [2],
there is an opportunity to use novel imaging approaches to
measure breast tissue properties related to an individual
woman’s response to risk reduction interventions. Our
findings, after further validation in larger prospective
studies, could be translated in the clinic to develop an
automated tool for integrated breast MRI assessment and
RRSO response prediction to aid clinical decision making.
As such, our proposed imaging biomarkers could result in
a more effective, evidence-based approach for risk reduc-
tion management of high-risk women using measures of
individualized response to each intervention. Such a
personalized approach for tailored risk reduction could
improve risk management, quality of life, and ultimately
outcomes for women at high risk for breast cancer.
Additional file
Additional file 1: Figure S1. Determination of an optimal parameter
value for BPE quantification using leave-one-out cross validation. This
supplemental material describes what value is identified by using
leave-one-out cross-validation as an optimal threshold for parameter
R%cutoff for quantifying BPE.
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